Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Eli Lilly has agreed to acquire privately held biopharma company SiteOne Therapeutics, adding a non-opioid-based pain treatment to the big pharma’s pipeline. The sale agreement will see Eli ...

Eli Lilly LLY recently announced that it has entered into a definitive agreement to acquire the privately held clinical-stage company SiteOne Therapeutics in a deal valued at $1 billion.

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Eli Lilly LLY 1.34% agreed to acquire Verve Therapeutics VERV -0.37% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne Therapeutics Inc. in a deal worth up to $1 billion.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal focused on treating hearing loss. The centerpiece of the agreement is ...

INDIANAPOLIS — Indianapolis-based pharmaceutical giant Eli Lilly and Company will invest up to $250 million as part of an expanded partnership with Purdue University announced Friday, May 9. The ...